Jade Biosciences Stock
Jade Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Tom Frohlich
- Employees
- 55
- Market cap
- $857 M
- IPO
- 30/06/2021
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company…
Jade Biosciences stock: price history
1D
-2.1%
1W
-6.4%
1M
-19.1%
6M
-41.1%
YTD
-12.7%
1Y
+37.6%
2Y
-83.7%
5Y
-97.3%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~153% stronger price swings than usual
Ask the agents about Jade Biosciences
Analyst assessment of Jade Biosciences
PRICE TARGET LOW
US$45.00
CONSENSUS
US$47.83
MEDIAN
US$47.00
PRICE TARGET HIGH
US$55.00
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 01/10/2026
Jade Biosciences stock metrics
P/E
-4.9
P/B
1.87
EV/EBITDA
-4.8
RETURN ON EQUITY
-12.7%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.7%
FLOAT SHARES
51,973,057
AVG. DAILY VOLUME (30D)
1,048,931
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Jade Biosciences stock
What does Jade Biosciences do?
Jade Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Tom Frohlich, the company employs around 55 people.
The IPO was on 30/06/2021; the stock trades on NASDAQ under the ticker JBIO.
What do analysts say about Jade Biosciences stock?
4 analysts rate the stock, the consensus is Buy (as of 01/10/2026).
The average price target is US$47.83, ranging from US$45.00 to US$55.00, with a median of US$47.00.
This is an external assessment, not a statement by Market Jury.
When does Jade Biosciences report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 153% stronger than usual.
Does Jade Biosciences pay a dividend?
Yes. The last dividend was US$2.40 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Jade Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Jade Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Jade Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.